CORDIS · 261409 · FP7
MEDIA The MEtabolic Road to DIAstolic Heart Failure
Coordinator: STICHTING AMSTERDAM UMC (NL)
More than 50% of heart failure (HF) patients present without a major deficit of left ventricular (LV) systolic function and are presumed to suffer from diastolic HF (DHF) because diastolic LV distensibility is usually impaired in these patients. The vast majority (~80%) of DHF patients is exposed to metabolic risk factors. The MEDIA consortium therefore investigates:1) how metabolic derangements contribute to DHF; 2) how diagnostic algorithms for DHF can be improved by assessing metabolic risk; 3) how correction of metabolic risk can open new therapeutic perspectives for DHF.Hereto MEDIA will…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €12.0M awarded to the consortium. The project runs over approximately 5.5 years from 2011-01-01 to 2016-06-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from NL
see all →- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · H2020 · €92.5M
- GN5-2 — GN5-2101194278 · HORIZON · €80.0M
- GN4-3 — Horizon 2020: H2020-SGA-INFRA-GEANT-2018 (Topic [a] Research and Education Networking)856726 · H2020 · €77.5M
- GN4-2 — GN4-2 Research and Education Networking - GÉANT731122 · H2020 · €59.0M
- GN5-1 — GN5-1101100680 · HORIZON · €55.0M
- BIGPICTURE — Central Repository for Digital Pathology945358 · H2020 · €32.3M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-IP funding scheme.
- What is the EU contribution?
- The European Commission contributes €12.0M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by STICHTING AMSTERDAM UMC (NL).
- What is the project timeline?
- The project runs from 2011-01-01 to 2016-06-30 — approximately 5.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 261409.